Is PLATELET COUNT DECREASED a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed PLATELET COUNT DECREASED.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 81 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported PLATELET COUNT DECREASED to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and PLATELET COUNT DECREASED. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause PLATELET COUNT DECREASED, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes PLATELET COUNT DECREASED. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if PLATELET COUNT DECREASED ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing PLATELET COUNT DECREASED: 81
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where PLATELET COUNT DECREASED is a reported side effect: 2.4332%

FDA reports of any drug causing PLATELET COUNT DECREASED : 32376
Average percentage for all medicated patients where PLATELET COUNT DECREASED is reported as a complication: 0.2029%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with PLATELET COUNT DECREASED:

REVLIMID (2796 patients)
ASPIRIN (2194 patients)
LASIX (1811 patients)
PREDNISOLONE (1632 patients)
PEGASYS (1565 patients)
HEPARIN SODIUM INJECTION (1469 patients)
NPLATE (1426 patients)
DEXAMETHASONE (1401 patients)
NEXAVAR (1393 patients)
RIBAVIRIN (1315 patients)
ALLOPURINOL (1305 patients)
CLOZARIL (1282 patients)
GLEEVEC (1279 patients)
VELCADE (1205 patients)
CYCLOPHOSPHAMIDE (1028 patients)
OMEPRAZOLE (975 patients)
DECADRON (969 patients)
PREDNISONE (937 patients)
SOLIRIS (906 patients)
CARBOPLATIN (899 patients)
CISPLATIN (895 patients)
METHOTREXATE (877 patients)
ZOMETA (870 patients)
FUROSEMIDE (865 patients)
FAMOTIDINE (862 patients)
FOLIC ACID (836 patients)
ACETAMINOPHEN (833 patients)
PEG-INTRON (809 patients)
EXJADE (773 patients)
REBETOL (742 patients)
LANSOPRAZOLE (740 patients)
LIPITOR (729 patients)
NORVASC (724 patients)
SUTENT (710 patients)
FLUOROURACIL (674 patients)
COUMADIN (674 patients)
PREDONINE (667 patients)
LISINOPRIL (653 patients)
CYTARABINE (648 patients)
COPEGUS (648 patients)
OXYCONTIN (615 patients)
SIMVASTATIN (609 patients)
ATENOLOL (594 patients)
ACYCLOVIR (578 patients)
TASIGNA (568 patients)
PLAVIX (559 patients)
MAGNESIUM OXIDE (558 patients)
POTASSIUM CHLORIDE (554 patients)
SUNITINIB MALATE (552 patients)
DIOVAN (546 patients)
HEPARIN (545 patients)
DOXORUBICIN HCL (535 patients)
REMICADE (531 patients)
SYNTHROID (529 patients)
FLUCONAZOLE (526 patients)
ETOPOSIDE (517 patients)
LOXONIN (513 patients)
WARFARIN SODIUM (502 patients)
GEMZAR (502 patients)
NEUPOGEN (501 patients)
ZOFRAN (500 patients)
MYLOTARG (492 patients)
NEXIUM (485 patients)
ALDACTONE (481 patients)
PROTONIX (478 patients)
AVASTIN (467 patients)
DEXAMETHASONE TAB (467 patients)
ZYVOX (461 patients)
DIFLUCAN (460 patients)
LEVOTHYROXINE SODIUM (460 patients)
MUCOSTA (459 patients)
VANCOMYCIN (444 patients)
CYCLOSPORINE (443 patients)
LEVOFLOXACIN (436 patients)
OXALIPLATIN (435 patients)
ENBREL (435 patients)
NEORAL (435 patients)
AMLODIPINE (430 patients)
ZYPREXA (424 patients)
URSO 250 (422 patients)
VOLTAREN (419 patients)
LORAZEPAM (415 patients)
DIGOXIN (410 patients)
RITUXIMAB (407 patients)
PREDNISONE TAB (402 patients)
PROGRAF (399 patients)
KYTRIL (393 patients)
ATIVAN (389 patients)
BACTRIM (383 patients)
MORPHINE (380 patients)
TEGRETOL (373 patients)
VIDAZA (369 patients)
TAXOL (356 patients)
ZOLOFT (356 patients)
LOVENOX (354 patients)
HYDROCHLOROTHIAZIDE (353 patients)
PRILOSEC (351 patients)
DEPAKENE (350 patients)
VINCRISTINE (349 patients)
AMBIEN (347 patients)
COMPAZINE (346 patients)
LYRICA (345 patients)
XANAX (342 patients)
RITUXAN (337 patients)
SULFAMETHOXAZOLE AND TRIMETHOPRIM (337 patients)
NEURONTIN (336 patients)
IBUPROFEN (336 patients)
RABEPRAZOLE SODIUM (335 patients)
PACLITAXEL (334 patients)
INSULIN (332 patients)
TAKEPRON (329 patients)
KEPPRA (328 patients)
GABAPENTIN (326 patients)
METOPROLOL TARTRATE (323 patients)
VALTREX (314 patients)
HEPARIN SODIUM (309 patients)
PROCRIT (308 patients)
ALBUTEROL (307 patients)
FOSAMAX (307 patients)
ALLEGRA (306 patients)
LEXAPRO (303 patients)
MAGMITT (300 patients)
AMARYL (299 patients)
ZANTAC (299 patients)
SOLU-MEDROL (292 patients)
PAXIL (291 patients)
ITRACONAZOLE (289 patients)
AFINITOR (289 patients)
MEROPENEM (289 patients)
METFORMIN HCL (286 patients)
LEVAQUIN (286 patients)
PLATELETS (285 patients)
VITAMIN B-12 (284 patients)
RIBASPHERE (284 patients)
PEGINTERFERON ALFA-2A (284 patients)
SPIRONOLACTONE (283 patients)
SELBEX (281 patients)
VITAMIN D (281 patients)
XIGRIS (280 patients)
LANTUS (280 patients)
CIPROFLOXACIN (279 patients)
XELODA (278 patients)
TOPROL-XL (276 patients)
FENTANYL (274 patients)
ZOCOR (273 patients)
CARVEDILOL (273 patients)
CRESTOR (272 patients)
GASTER (271 patients)
AMLODIPINE BESYLATE (270 patients)
TOCILIZUMAB (270 patients)
VICODIN (268 patients)
RAMIPRIL (267 patients)
ARANESP (267 patients)
VIOXX (266 patients)
BAKTAR (265 patients)
OMEPRAL (265 patients)
BENADRYL (264 patients)
OXYCODONE HCL (261 patients)
RISPERDAL (260 patients)
GEMCITABINE (260 patients)
PROMACTA (259 patients)
VALPROATE SODIUM (258 patients)
LACTULOSE (255 patients)
TAXOTERE (254 patients)
PREVACID (253 patients)
SEROQUEL (251 patients)
RED BLOOD CELLS (250 patients)
PURSENNID (250 patients)
TELAVIC (TELAPREVIR) (249 patients)
HUMIRA (249 patients)
CELEBREX (246 patients)
CAPECITABINE (244 patients)
MULTI-VITAMINS (243 patients)
METHYLPREDNISOLONE (241 patients)
DEPAKOTE (240 patients)
BEVACIZUMAB (240 patients)
AREDIA (239 patients)
TEMAZEPAM (238 patients)
CLOZAPINE (238 patients)
TEMOZOLOMIDE (237 patients)
MAGNESIUM OXIDE (MAGNESIUM OXIDE) (237 patients)
THALOMID (233 patients)
EPOGEN (232 patients)
AVONEX (231 patients)
RANITIDINE (230 patients)
ALPRAZOLAM (230 patients)
ALIMTA (229 patients)
PEPCID (229 patients)
FERROUS SULFATE TAB (229 patients)
CORTICOSTEROIDS (227 patients)
TEMODAL (224 patients)
COZAAR (224 patients)
LAMOTRIGINE (223 patients)
BENDAMUSTINE HCL (223 patients)
NEULASTA (221 patients)
DEXAMETHASONE SODIUM PHOSPHATE (220 patients)
ONDANSETRON (220 patients)
DIAZEPAM (220 patients)
RADIATION THERAPY (218 patients)
ENALAPRIL MALEATE (218 patients)
RHEUMATREX (217 patients)
MAXIPIME (215 patients)
LENADEX (215 patients)
SPRYCEL (215 patients)
DEXAMETHASONE ACETATE (214 patients)
TRACLEER (211 patients)
CLONAZEPAM (205 patients)
GASTER D (205 patients)
CELLCEPT (205 patients)
CALCIUM (204 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about PLATELET COUNT DECREASED and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.